Publication

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59

ANNÉE

2022

AUTEURS

Evrard C, Aparicio T, Soularue E, Le Malicot K, Desramé J, Botsen D, El Hajbi F, Gonzalez D, Lepage C, Bouché O, Tougeron D, On Behalf Of The Durigast-Prodige Investigators/Collaborators

CONGRÈS/REVUE

Biomedicines

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.3390/biomedicines10051211

SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

ANNÉE

2022

AUTEURS

Boisteau E, François E, Aparicio T, Le Malicot K, Boulahssass R, Lecomte T, Laurent-Puig P, Guiu B, Paillaud E, Galais MP, Lopez-Trabada Ataz D, Tougeron D, Dourthe LM, Guimbaud R, Samalin E, Moreau M, Louvet C, Lepage C, Lièvre A

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2022.03.001

Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

ANNÉE

2022

AUTEURS

Taieb J, Bouche O, André T, Barbier E, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Buecher B, H. Perrier H, Di Fiore F, Gallois C, Lepage C, El Hajbi F, Tougeron D

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/avelumab-versus-standard-second-line-treatment-chemotherapy-in-metastatic-colorectal-cancer-mcrc-patients-with-microsatellite-instability-msi

Lichenoid eruption during antiPD-L1 immunotherapy with avelumab in metastatic colorectal cancer

ANNÉE

2022

AUTEURS

Brayer M, Lepage C, Taieb J, Tougeron D

CONGRÈS/REVUE

Clin Res Hepatol Gastroenterol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.clinre.2022.101924

Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial

ANNÉE

2022

AUTEURS

Winter A, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C

CONGRÈS/REVUE

Qual Life Res

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1007/s11136-022-03252-6

Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials

ANNÉE

2022

AUTEURS

Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C

CONGRÈS/REVUE

Qual Life Res

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1007/s11136-021-03040-8

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

ANNÉE

2022

AUTEURS

Pernot S, Pellerin O, Mineur L, Monterymard C, Smith D, Lapuyade B, Gallois C, Khemissa Akouz F, De Baere T, Tougeron D, Thirot-Bidault A, Audemar F, Simon M, Lecaille C, Louafi S, Lepage C, Ducreux M, Taieb J

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2021.12.012

Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

ANNÉE

2022

AUTEURS

Walter T, Lievre A, Coriat R, Malka D, El Hajbi F, Di Fiore F, Hentic-Dhome O, Smith D, Hautefeuille V, Roquin G, perrier M, Dahan L, Granger V, Sobhani I, Mineur L, NICCOLI P, Assenat E, Le Malicot K, Lepage C, Lombard Bohas C

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/bevacizumab-b-plus-folfiri-after-failure-of-platinum-etoposide-in-patients-pts-with-advanced-neuroendocrine-carcinoma-nec-the-prodige-41-bev

STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer A GERCOR-PRODIGE randomized open-label phase III study.

ANNÉE

2022

AUTEURS

Chibaudel B, Dourthe L-M, Andre T, Henriques J, Bourgeois V, Etienne P-L, Desrame J, Carola E, Dupuis O, Baba-Hamed N, Auby D, Louvet C, Maillard E, Romano O, Tournigand C, Garcia-Larnicol ML, Shacham Shmueli E, Healey Bird B, Ghiringhelli F, De Gramont A

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3504

Impact of age on treatment strategies in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): A prespecified subgroup analysis of the GERCOR-PRODIGE STRATEGIC-1 phase III study

ANNÉE

2022

AUTEURS

Carola E, Chibaudel B, Boulahssass R, Dourthe LM, André T, Henriques J, Bourgeois V, Etienne P, Desrame J, Dupuis O, Baba-Hamed N, Auby D, Louvet C, Maillard E, Tournigand C, Garcia-Larnicol ML, Shacham Shmueli E, Bird BH, Ghiringhelli F, De Gramont A

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/impact-of-age-on-treatment-strategies-in-ras-braf-wild-type-metastatic-colorectal-cancer-mcrc-a-prespecified-subgroup-analysis-of-the-gercor-pro